Compare Infosys Limited (INFY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Neurocrine Biosciences Inc — how do they compare? Infosys Limited trades at $10.8 (market cap $41.74B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Infosys Limited is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and Infosys Limited pays a 4.89% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Neurocrine Biosciences Inc for 23 Days on average.
| INFY | NBIX | |
|---|---|---|
Market Cap | $41.74B | $14.36B |
Volume | 31,354,285 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $20.22 | $185.50 |
52-Week Low | $10.49 | $123.10 |
Typical Hold Time | 27 Days | 23 Days |
Enterprise Value | $39.48B | $14.37B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
